Related Experiment Videos
beta-Blockers in congestive heart failure
1The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1030, New York, NY 10029, USA.
Abstract:
Recent advances in the understanding of the basic mechanisms underlying congestive heart failure (CHF) have focused on the role of neurohormonal activation. Chronic adrenergic overstimulation is directly toxic to myocardial cells, impairs function, causes peripheral vasoconstriction and may induce programmed cell death via apoptosis. beta-Adrenergic blockade can interrupt this pathological process. Accumulating evidence now points to a clear role for beta-blocking agents in the management of heart failure, reducing both the morbidity and mortality associated with CHF. This report will review the recent clinical trials supporting the use of beta-blockers in CHF, briefly highlight some practical considerations in the use of these drugs in patients with CHF and discuss several areas of controversy in which further study is needed.
Insights
Beta-blockers interrupt pathological processes in congestive heart failure (CHF) by blocking chronic adrenergic overstimulation. Clinical trials demonstrate their effectiveness in reducing CHF morbidity and mortality.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) involves neurohormonal activation, particularly chronic adrenergic overstimulation.
- This overstimulation is toxic to myocardial cells, impairs cardiac function, and can lead to apoptosis.
Purpose of the Study:
- To review clinical trials supporting beta-blocker use in CHF management.
- To discuss practical considerations and controversies regarding beta-blockers in CHF patients.
Main Methods:
- Review of recent clinical trials on beta-blockers in heart failure.
- Analysis of mechanisms of action and clinical evidence.
Main Results:
- Beta-adrenergic blockade effectively interrupts the pathological process of adrenergic overstimulation in CHF.
- Evidence supports beta-blockers in reducing morbidity and mortality associated with CHF.
Conclusions:
- Beta-blockers are crucial in managing congestive heart failure.
- Further research is needed in specific areas of controversy regarding their use.